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DNA profiling and cytogenetic analysis of cell line WSU-CLL reveal crosscontamination with cell line REH (pre B-ALL)
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TO THE EDITOR Leukemia-lymphoma cell lines represent invaluable resources for the investigation of an endless variety of cellular and molecular processes in vitro. While certain experimental results obtained in cell culture lend themselves to a global interpretation applicable for a whole class of cells (eg for all hematopoietic cells), in other investigations where experimental data are specific for rather narrowly defined types of cells (eg a defined maturation stage within one hematopoietic cell lineage or a specific subtype of hematopoietic malignancy), it is of the utmost importance that the in vitro model cell line corresponds as closely as possible to its original tumor. In other words, it is inappropriate to extrapolate B cell-specific findings to monocytes. Otherwise, why bother with complex cell lines which are difficult to grow and not just simply use some easier cell lines such as HL-60, K-562 or U-937 and boldly extrapolate the results across cell lineages to the desired target cells?
Hence, it is absolutely necessary to identify precisely the cell lineage and stage of arrested differentiation of a leukemia-lymphoma cell line. However, besides the exact characterization it is also mandatory to verify the derivation of that cell line from the presumed patient by unequivocal methods such as forensic-type DNA profiling, cytogenetic karyotyping, etc.
Unfortunately, a large percentage of leukemia-lymphoma cell lines are cross-contaminated 1 with the consequence that in many instances these cell lines cannot be used as the specific in vitro models which they are supposed to be. To add fuel to the fire, original investigators who have generated the cross-contaminations or researchers who have used the false cell lines, when informed about the true nature of the cell line, are all too often reluctant to believe these facts or simply ignore them, a phenomenon which we termed the 'false cell line denial syndrome'. Clearly, the widespread and consistent use of misidentified cell lines leads to inaccurate data. The cell line WSU-CLL was reported to be derived from the peripheral blood sample of a 68-year-old black male with therapy-resistant B-CLL in terminal phase in 1992. 3 In comparison with other bona fide B-CLL cell lines, WSU-CLL presented the following remarkable features: (1) the cells were EBV-negative; all other B-CLL cell lines are EBV + ; (2) the cells were CD5 − CD10 + ; this immunoprofile pattern has not been reported in other B-CLL cell lines. Of particular importance are two facts: (1) the cell line was not authenticated, that means it was not proven by DNA profiling or other unequivocal genetic approaches (marker chromosomes, Southern blot banding patterns of IGH rearrangements, etc) that the cell line was indeed established from this patient; (2) the complete karyotype of the cell line was presented in written and pictorial form in the original publication. 3 We observed the following consensus karyotype for WSU-CLL cells held at the DSMZ: 45<2n>X-Y, del(3)(p21p24.2), der(4)t(4;21)(q31;q22), der (5) 
Figure 1
AmpFLP and high-resolution STR DNA profiles. DNA typing of the indicated cell lines was carried out using Apo-B1, D17S5, D1S80, D2S44, PAH and Col2A as polymorphic VNTR markers for PCR amplification as described previously. 2 The obtained PCR products of specific VNTRs were run separately on a 1.2% agarose gel for size determination of the amplicons and comparison within the DNA profile database (data not shown) and together in a single lane (upper part). A multiple-locus DNA profile was generated using 10 g of genomic DNA digested to completion (HinfI), size-separated on a 0.7% agarose gel and blotted on positively charged nylon membranes. After hybridization to a digoxigenin-labelled (GTG) 5 oligo as probe, a chemiluminescent detection was carried out and the blot was exposed for 1 h to X-ray film. Molecular weight markers were used for size determination. Cervix carcinoma cell line HeLa was used as positive control in AmpFLP analysis.
Figure 2
Identification of TEL-AML1 fusion by RT-PCR. RNAs derived from REH cell cultures (REH-ATCC and REH-DSMZ), WSU-CLL and human tongue squamous cell carcinoma CAL-33 (negative control) were used in a RT-PCR reaction with the sense primer TEL969 and the antisense primer NAML1. 4 The amplification products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. The integrity of the RNA and cDNA and the fidelity of the PCR reaction were demonstrated by amplification of the ABL transcript using F-ABL-A2 (5Ј-TGA CTT TGA GCC TCA GGG TCT GAG TGA AGC C-3Ј) and R-ABL-A3 (5Ј-CCA TTT TTG GTT TGG GCT TCA CAC CAT TCC-3Ј).
(q31;p13)dup(12)(q14q21), der(12)t(12;21)(p13;q22)inv(12)(p13q22), der(16)t(16;21) (q23-24;q21-22)x2, der(18;21)(q10;q10), der(21)t(12;21)(p13;q22), ie closely resembling the original karyotype published for this cell line. 3 Thus, DSMZ stocks of the WSU-CLL cell line fairly represent that described by their originators. However, this karyotype also resembles in detail that which we previously determined for REH. 4 In particular, both cell lines carry complex four-way translocations involving breakpoints at 4q31, 12p13 (ETV6), 16q23-24 and 21q22 (AML1), together with parallel rearrangement of band p13 of the homologous chromosome 12. This series of chromosome 
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Figure 3
Immunofluorescence analysis of CD138 expression. REH (DSMZ), REH (ATCC) and WSU-CLL cells were stained with a specific antibody (CD138, clone ID4; Dianova, Hamburg, Germany). Cell surface expression was examined by flow cytometry (FACScan, Becton Dickinson, Heidelberg, Germany). Background staining with an isotype control antibody is shown as an open curve. changes is anything other than random, effecting t(12;21) together with microdeletion of the residual 12p13/ETV6 region, ie as commonly observed in primary BCP-ALL. However, the underlying cytogenetic mechanism is unique to REH where its occurrence is appropriate, and WSU-CLL where it is not. Importantly, our data revealed a karyotype essentially identical to the karyotype published for WSU-CLL, allowing us to rule out that these aberrations occurred during in vitro propagation in our laboratory.
We have had the opportunity to compare the DNA profile of WSU-CLL cells which we had obtained directly from the original investigators with those of over 500 human leukemia-lymphoma cell lines stored in our DNA profiles databank. 5 We found identical single-locus and multi-locus DNA profiles (Figure 1 ) for WSU-CLL and two independently sourced stocks of cell line REH, respectively, deposited at the DSMZ cell lines bank, 5 and obtained from the American Type Culture Collection (ATCC). REH was established in 1974 from the peripheral blood of a 15-year-old girl with acute lymphoblastic leukemia at relapse. 2 The lineage and stage of arrested differentiation of cell line REH corresponds to that of a B cell precursor (BCP). Further evidence was provided by the detection of the TEl-AML1 (now known as EVT6-RUNX1) fusion gene which results from the t(12;21)(p13;q22) and which occurs only in primary and cultured BCP cells (including cell line REH); 4 all three cell cultures examined showed this genetic abnormality (Figure 2) . Cytogenetic analysis has shown that the TEL-AML1 fusion is generated in REH by a unique four-way translocation, t(4;12;21;16) 4 which we have now confirmed in WSU-CLL. Taken together, WSU-CLL is definitely only a subclone of cell line REH and is hence a BCP cell line.
It has been reported that there are significant phenotypic differences between WSU-CLL and REH. For instance, while WSU-CLL grows very well in SCID mice, REH cells allegedly do not grow in these animals. However, a literature search shows that different investigators were able successfully to heterotransplant REH cells into nude and SCID mice. 6 Nevertheless, it is well known that subclones derived explicitly or inadvertently from their parental cultures can develop quite divergent phenotypic features. A good case in point is the widely distributed cell line K-562 for which quite dramatic phenotypic differences between subcultures with regard to growth kinetics, cloning efficiency and hemoglobin production have been noted. 7 A large panel of K-562 sublines shared several common surface antigens but expressed a marked diversity and variability of other markers. 8 In this context, we examined the expression of a panel of immunomarkers on the cell lines WSU-CLL, REH (ATCC) and REH (DSMZ) ( Table 1) . It became evident that these genotypically identical cell lines express some phenotypic markers to various extents, eg CD20, CD34, CD138 (Figure 3) .
In summary, different approaches have revealed that the WSU-CLL cell line is indeed the REH cell line and most likely resulted from an inadvertent cross-contamination during cell culture at the original source, presumably during the attempts to establish a B-CLL cell line. Hence, WSU-CLL is a subclone of BCP-ALL cell line REH and it is clearly inappropriate to use WSU-CLL as a model for B-CLL. TO THE EDITOR Treatment of relapsed AML is difficult, especially if remission duration was short, if it is later than first relapse, if karyotype is unfavourable or if the patient is not eligible for intensive treatment. We report a case of a 76-year-old female patient presenting with all these unfavourable predictors. Remarkably, this patient entered a third complete remission (CR) following a single dose of gemtuzumab ozogamicin (CMA-676), and CR duration with low-dose interleukin-2 (IL-2) maintenance now exceeds 11 months.
The patient was first diagnosed with AML, FAB M5, with t(1;21)(q21;q22) in October 1998. The patient was treated with cytarabine, daunorubicin and the multidrug resistance modulator PSC 833 for induction resulting in CR, followed by two consolidation chemotherapies which consisted of cytarabine, daunorubicin and PSC 833 (consolidation 1), and cytarabine, mitoxantrone and etoposide (consolidation 2). Treatment was complicated by profuse peranal bleeding during pancytopenia following induction.
Fourteen months later the patient was readmitted with first relapse of AML. Treatment with mitoxantrone, etoposide and cytarabine, resulted again in CR. One cycle of consolidation therapy was adminis- Another 6 months later the patient was readmitted with her second recurrence of AML and t(1;22)(p11;p11) was observed as second cytogenetic aberration. Treatment with oral low-dose melphalan (2 mg/day) was initiated. This treatment has been shown to be well tolerated and effective in some patients with secondary AML. 1 However, re-evaluation 4 weeks later demontrated progressive pancytopenia, increased marrow blast counts and del(1)(q21) as the third cytogenetic abnormality.
The patient was well informed about her prognosis and agreed on a single dose of CMA-676 (9 mg/m 2 ), although administration of two doses is generally recommended.
2 CMA-676 is a humanized murine anti-CD33 antibody linked to the potent tumor antibiotic Nac-gamma calicheamicin. Calicheamicin exerts its toxic effects only after cleavage from the antibody following incorporation into CD33-positive cells; toxin bound to antibody is inactive.
3 CD33 is brightly expressed on most AML blasts and on some myeloid precursors, but scarcely expressed in non-myeloid tissues and absent on hematopoietic stem cells. 4 Distribution of CD33 antigen and properties of the immunotoxin explain anti-AML selectivity of CMA-676 compared to conventional chemotherapeutic drugs. In 142 patients with CD33-positive AML in first relapse a 30% overall remission rate was achieved. 5 In our patient, leukemic blasts highly expressed the CD33 antigen and treatment with CMA-676 was effective and well tolerated: bone marrow aspirate on day 40 showed complete clearance of leukaemic blasts. The major adverse reaction was prolonged pancytopenia asso-
